HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Han, Q.-Q. Articles by Huang, S.-D. Search for Related Content PubMed PubMed Citation Articles by Han, Q.-Q. Articles by Huang, S.-D. Related Collections Valve disease

Eur J Cardiothorac Surg 2007;31:845-850. doi:10.1016/j.ejcts.2007.02.005
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved

Primary triple valve surgery for advanced rheumatic heart disease in Mainland China: a single-center experience with 871 clinical cases

Department of Cardiothoracic Surgery, Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China

Received 5 December 2006; received in revised form 28 January 2007; accepted 2 February 2007.

^_* Corresponding author. Address: Department of Cardiothoracic surgery, Changhai Hospital, 174 Changhai Road, Shanghai 200433, People's Republic of China. Tel.: +86 21 25072914; fax: +86 21 65490979. (Email: xuzhiyun{at}gmail.com).

Background: Triple valve surgery (TVS) is still of choice for advanced rheumatic heart disease (RHD), which has been associated with reported poor early and late outcomes. We describe the short- and long-term results after TVS in last two decades in Mainland China. Methods: From January 1985 to January 2005, a total of 871 patients (217 men, 654 women), with mean age of 42 ± 11 years, underwent primary TVS for isolated advanced RHD. All patients received replacement procedures in mitral and aortic position (845 mechanical, 26 bioprosthetic), and 840 patients received repair procedures and the other 31 received replacement procedures in tricuspid position (9 mechanical, 22 bioprosthetic). Preoperative, perioperative, and postoperative data were retrospectively analyzed and risk factors affecting early and late survival were evaluated. Results: The 30-day hospital mortality was 8% (n = 71). Presence of ascites, New York Heart Association (NYHA) class IV and lower left ventricular ejection fraction (LVEF) were identified as independent risk factors for hospital mortality. Overall long-term survival rate was 71% ± 3% at 5 years, and 59% ± 5% at 10 years. The cardiac survival rate was 75% ± 3% at 5 years and 63% ± 4% at 10 years. The event-free survival rate at 5 years and 10 years was 61% ± 6% and 41% ± 13%, respectively. Multivariate analysis revealed advanced age, NYHA class IV and lower LVEF were associated with increased late mortality. The freedom from thromboembolism and anticoagulation-related hemorrhage at 10 years was 90% ± 4% and 81% ± 5%, respectively. Of the 508 patients still alive, 376 (74%) were in NYHA class I and II. Conclusions: Primary TVS for advanced RHD appears to offer satisfactory short- and long-term results with excellent symptomatic improvement. Cardiac-related late mortality following TVS may be improved by early surgical treatment before NYHA class IV or deterioration of LVEF occurs.

Key Words: Triple valve surgery • Rheumatic heart disease • New York Heart Association functional class • Left ventricular ejection fraction • Anticoagulation

This article has been cited by other articles:

				J. M. Bernal, A. Ponton, B. Diaz, J. Llorca, I. Garcia, A. Sarralde, C. Diago, and J. M. Revuelta Surgery for rheumatic tricuspid valve disease: a 30-year experience. J. Thorac. Cardiovasc. Surg., August 1, 2008; 136(2): 476 - 481. [Abstract] [Full Text] [PDF]